TLSI – trisalus life sciences, inc. (US:NASDAQ)
Stock Stats
News
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $11.00 price target on the stock.
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping [Yahoo! Finance]
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
Form NT 10-K TriSalus Life Sciences, For: Dec 31
Form 8-K TriSalus Life Sciences, For: Mar 27
Form 8-K TriSalus Life Sciences, For: Feb 19
Form 4 TriSalus Life Sciences, For: Feb 18 Filed by: Murphy Sean
Form 4 TriSalus Life Sciences, For: Feb 18 Filed by: Young James Emmett
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.